[Antitumor activity of cis-dichlorodiammineplatinum(II) and its effect on cell cycle progression].
Antitumor activity of cis-dichlorodiammineplatinum(II) (cisplatin) on various mouse transplantable tumors was investigated. Cisplatin was active against a wide variety of the following tumor systems: L1210 leukemia, P388 leukemia, B16 melanoma, colon tumor 38, Ehrlich ascites and solid carcinoma, WHT squamous cell carcinoma, and human stomach cancer G/S heterotransplanted in nude mice. From the comparison of growth inhibitory effect by cisplatin with various other antitumor agents in cultured Ehrlich ascites carcinoma cells, cisplatin was found to be mainly a concentration depending drug, but also time depending, so that it was identified as a type Ib class drug proposed by Shimoyama. Effect of cisplatin on the cell cycle progression of Ehrlich ascites carcinoma cells in mice was studied by flow cytometry of DNA. At an early stage after administration of cisplatin, cell cycle progression was delayed in S phase and blocked in G2 phase. With the elapse of time block in G1 phase or G1-S boundary was observed and the cell population, partially synchronized in G1 phase or G1-S boundary, progressed slowly through S phase to be blocked in G2 phase finally.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology*; D007939:Leukemia L1210 / Q000473:pathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009369:Neoplasms / Q000473:pathology*; D013274:Stomach Neoplasms / Q000473:pathology
D002945:Cisplatin